Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated at StockNews.com
StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research report released on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock. Several other analysts have also recently commented on the company. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a […]
More Stories
Weekly Market Review: Stocks Post Losses Despite Falling Treasury Yields
By Panos Mourdoukoutas Volatility continued this week on Wall Street, with stocks posting losses despite a decline in Treasury bond...
Bank of Montreal Can Cuts Holdings in iShares Global Clean Energy ETF (NASDAQ:ICLN)
Bank of Montreal Can lowered its holdings in iShares Global Clean Energy ETF (NASDAQ:ICLN – Free Report) by 27.9% in...
Trump Floats Revoking Harvard’s Tax-Exempt Status—What Is It?
By Aaron Gifford Harvard University and the Trump administration are in an escalating standoff after the institution declined to comply...
Pentagon to Wind Back US Troop Footprint in Syria
By Ryan Morgan The Pentagon is preparing to downsize the U.S. military footprint in Syria in the coming weeks, citing...
UBS Group Lowers NVIDIA (NASDAQ:NVDA) Price Target to $180.00
NVIDIA (NASDAQ:NVDA – Get Free Report) had its target price cut by stock analysts at UBS Group from $185.00 to...
Cantor Fitzgerald Cuts Alphabet (NASDAQ:GOOGL) Price Target to $159.00
Alphabet (NASDAQ:GOOGL – Free Report) had its target price lowered by Cantor Fitzgerald from $200.00 to $159.00 in a report...